CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS - USD ($) $ in Thousands		3 Months Ended
		Mar. 31, 2025	Mar. 31, 2024
Operating expenses:
Research and development		$ 5,818	$ 10,537
Selling, general and administrative		11,113	5,551
Total operating expenses		16,931	16,088
Loss from operations		(16,931)	(16,088)
Other income (expense):
Other expense		(11)	(1,348)
Interest income		2,323	788
Total other income (expense), net		2,312	(560)
Net loss		(14,619)	(16,648)
Other comprehensive loss:
Unrealized loss on marketable securities		(73)	(7)
Comprehensive loss		$ (14,692)	$ (16,655)
Net loss per share - basic (in dollars per share)		$ (0.53)	$ (3.53)
Net loss per share - diluted (in dollars per share)		$ (0.53)	$ (3.53)
Weighted-average common shares outstanding, basic (in shares)	[1]	27,526,099	4,717,613
Weighted-average common shares outstanding, diluted (in shares)	[1]	27,526,099	4,717,613

[1] See Note 2 for further information on weighted-average common shares outstanding.